The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy.
Mary-Ellen Taplin
Consultant or Advisory Role - Tokai
Research Funding - Tokai
Robert B. Montgomery
Honoraria - Tokai
Research Funding - Tokai